ITMCTR1900002803
Not Yet Recruiting
Phase 1
Study for clinical efficacy evaluation and mechanism of Chinese medicine in relieving antibiotic resistance and sensitizing resistant bacteria by taking drug-resistant bacterial diarrhea as an example
Affiliated Hospital of Changchun University of Traditional Chinese Medicine0 sitesTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Drug-resistant bacterial diarrhea in children
- Sponsor
- Affiliated Hospital of Changchun University of Traditional Chinese Medicine
- Status
- Not Yet Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged 6 months to 14 years old;
- •2\. In line with the diagnostic standards of traditional Chinese and western medicine, the course of the disease is less than 2 weeks, and the disease is mild and medium;
- •Diagnostic criteria of western medicine: refer to the 8th edition of Zhu futang Practical Pediatrics in 2015 and Clinical Practice Guide for Acute Infectious Diarrheal Disease in Chinese Children formulated by Digestive Group of Pediatrics Branch of Chinese Medical Association in 2016\. If drug\-resistant bacteria are found in fecal culture, it is drug\-resistant bacterial diarrhea.Diagnostic criteria of Traditional Chinese Medicine: the relevant criteria for diarrhea, dampness and heat syndrome in children are formulated with reference to Pediatrics of Praditional Chinese Medicine, the 4th edition of the 13th Five\-year New Century, 2016\.
- •3\. White blood cell count \>\=5 /HPF in routine test, accompanied by the determination of procalcitonin or CRP or the percentage of neutrophils is higher than normal;
- •4\. Get the guardian's consent, fill in the informed consent form, and agree to participate in (children over 8 years old should sign the consent form).
Exclusion Criteria
- •1\. Bacterial diarrhea caused by cholera, dysentery, typhoid and paratyphoid (white blood cell count in stool \>\=15 /HPF, a small number of red blood cells can be seen);
- •2\. Severe dehydration, acidosis, shock, and immunodeficiency;
- •3\. Patients with serious diseases of cardiovascular, liver, kidney and hematopoietic system and mental illness;
- •4\. Acute diarrhea caused by intussusception and intestinal polyps;
- •5\. Patients who underwent surgery within 30 days before the test and caused diarrhea;
- •6\. Patients who failed to respond to treatment will be not included in this study;
- •7\. Patients who participated in other clinical trials within 1 months;
- •8\. Allergic constitution or be allergy to known components of the test drug.
- •Patients who meet any of the above criteria should be excluded.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 1
Clinical Efficacy Evaluation and Mechanism Study of Anti-Hepatic Fibrosis Effectively Treated Prescription by Supplementing Deficiency and Clearing CollateralsITMCTR2100005161Chengdu University of Traditional Chinese Medicine
Completed
N/A
Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanomamalignant melanomaJPRN-UMIN000016608Public Health Research Foundation128
Completed
N/A
Clinical study for the evaluation of the effectivity of different tooth brushes in inital treatment of periodontal diseased patientschronical periodontitisK05.3Chronic periodontitisDRKS00009642Poliklinik für Zahnerhaltung und Parodontologie72
Unknown
Phase 2
A clinical trial to study the effect of Unani drug in the treatment of liver cirrhosis.CTRI/2021/09/036474Deptt of Moalajat School of Unani Medical Education and Research Jamia Hamdard University
Not Yet Recruiting
N/A
A study to assess the clinical effectiveness and safety of intravesical mitomycin-C and gemcitabine sequential therapy in patients with high risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) Therapy: Prospective, multicenter, open-label trialKCT0009491ational Cancer Center82